INVO Fertility, Inc. (IVF) AI Stock Analysis

INVO Fertility, Inc. is a Sarasota, Florida-based healthcare services company focused on assisted reproductive technology care for patients. Operating through Fertility Clinic Services and INVOcell Device segments, the company provides the patented INVOcell Device, a medical device enabling fertilization and early embryo development to occur in vivo within a woman's body. In addition to medical device commercialization, the company operates fertility clinics under the INVO Centers brand. Founded in 2007 and employing 40 people, the organization was previously known as NAYA Biosciences, Inc. before changing its name to INVO Fertility, Inc. in April 2025.

Between FY2021 and FY2025, revenue increased from $4.2M to $6.8M, reflecting a 5-year revenue CAGR of 45.8%, despite a sharp drop to $822,196 in FY2022. Revenue climbed 116.3% to $6.5M in FY2024 and grew 4.7% to $6.8M in FY2025. Gross margin stood at 37.0% in FY2025, down from 44.0% in FY2024 and 96.5% in FY2021. Operating margin was -85.4% in FY2025, while net losses expanded from -$9.1M in FY2024 to -$23.3M in FY2025. For the trailing twelve months ended June 30, 2026, revenue reached $7.5M with an operating margin of -59.3%, supported by 16.7% quarterly revenue growth year-over-year.

As of June 30, 2026, INVO Fertility held $3.7M in cash and short-term investments against total debt of $3.9M, leaving net debt at $188,753. The company reported shareholders' equity of $16.5M, total assets of $25.8M, and a debt-to-equity ratio of 0.24, alongside a current ratio of 0.71. Operating cash flow remained negative at -$7.0M in FY2025, with free cash flow at -$7.1M. Cash utilization in FY2025 included $43,412 in capital expenditures and $4.0M in share buybacks, while the five-year share count increased by 647900.0%.

Trading at $0.56 as of October 16, 2026, INVO Fertility carries a market capitalization of $2.6M and an enterprise value of $3.1M. The stock trades at a price-to-sales ratio of 0.3x and an enterprise value-to-revenue multiple of 0.4x, both well below the median of its US-listed Healthcare peers at 4.1x and 12.0x EV/EBITDA. The price-to-book ratio is 0.2x. Over the past year, shares fell 99.0% compared to a 16.8% gain for the S&P 500, and the stock is down 77.5% relative to its 200-day average.

Wall Street coverage consists of 1 Buy rating and zero Hold or Sell ratings. The sole analyst provides a mean price target of $20.00, representing an upside of 3484.2% over the last close of $0.56. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $10.4M and EPS of -$23.20. For FY2027, expectations anticipate revenue rising 58.0% to $16.5M and EPS improving 65.5% to -$8.00. The company beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 16, 2026.

This page is an AI-written research summary of INVO Fertility, Inc. (IVF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IVF income statement, IVF balance sheet, IVF key metrics, IVF analyst forecast, IVF chart. See the IVF stock overview for the latest quote and news.